OGC
TAK icon

Oak Grove Capital’s Takeda Pharmaceutical TAK Stock Holding History

Oak Grove Capital’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-53,946
Closed -$1.1M – 75
2019
Q1 		$1.1M Buy
+53,946
New +$1.09M 0.69% 31

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Oak Grove Capital's TAK Position: Q2 2019 in Review

Oak Grove Capital sold out of Takeda Pharmaceutical (TAK) in Q2 2019, closing a stake of 53,946 shares — an estimated $1.1M sold.

Oak Grove Capital first reported a position in TAK in Q1 2019 and held it in 1 quarter. The position peaked at $1.1M in Q1 2019. 347 funds tracked by Wall St. Rank hold TAK as of Q2 2019.

  • Oak Grove Capital reported no remaining Takeda Pharmaceutical position as of Q2 2019 after selling out during the quarter.
  • Oak Grove Capital sold 53,946 Takeda Pharmaceutical shares in Q2 2019, an estimated $1.1M.
  • Oak Grove Capital first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 1 quarter.
  • Oak Grove Capital's Takeda Pharmaceutical position peaked at $1.1M in Q1 2019.
  • 347 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2019.

Based on Oak Grove Capital's 13F filing for Q2 2019, filed 9 Aug 2019.